There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vigil Neuroscience Inc (VIGL – Research Report), Verve Therapeutics (VERV – Research Report) and Coherus Biosciences (CHRS – Research Report) with bullish sentiments.
Vigil Neuroscience Inc (VIGL)
JMP Securities analyst Jason Butler reiterated a Buy rating on Vigil Neuroscience Inc today and set a price target of $23.00. The company’s shares closed last Tuesday at $6.65.
According to TipRanks.com, Butler is ranked 0 out of 5 stars with an average return of
Vigil Neuroscience Inc has an analyst consensus of Strong Buy, with a price target consensus of $18.25.
See today’s best-performing stocks on TipRanks >>
Verve Therapeutics (VERV)
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Verve Therapeutics today and set a price target of $55.00. The company’s shares closed last Tuesday at $17.78.
According to TipRanks.com, PhD is ranked #2161 out of 8601 analysts.
Verve Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $37.00, which is a 131.1% upside from current levels. In a report issued on October 24, Canaccord Genuity also maintained a Buy rating on the stock with a $29.00 price target.
Coherus Biosciences (CHRS)
In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Coherus Biosciences, with a price target of $15.00. The company’s shares closed last Tuesday at $2.78, close to its 52-week low of $2.56.
According to TipRanks.com, Nedelcovych is ranked #4127 out of 8601 analysts.
Coherus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $12.17, a 344.2% upside from current levels. In a report issued on October 23, Barclays also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIGL:
- Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
- Arm initiated, SQM downgraded: Wall Street’s top analyst calls
- Vigil Neuroscience initiated with an Outperform at JMP Securities
- Vigil Neuroscience announces first patient dosed in Phase 1 trial of VG-3927
- Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
